Rxivist logo

The rapid spread of SARS-CoV-2 has a significant impact on global health, travel and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated neutralizing antibodies from convalescent COVID-19 patients using a SARS-CoV-2 stabilized prefusion spike protein. Several of these antibodies were able to potently inhibit live SARS-CoV-2 infection at concentrations as low as 0.007 μg/mL, making them the most potent human SARS-CoV-2 antibodies described to date. Mapping studies revealed that the SARS-CoV-2 spike protein contained multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as previously undefined non-RBD epitopes. In addition to providing guidance for vaccine design, these mAbs are promising candidates for treatment and prevention of COVID-19. ### Competing Interest Statement Amsterdam UMC has filed a patent application on COVID-19 monoclonal antibodies.

Download data

  • Downloaded 3,680 times
  • Download rankings, all-time:
    • Site-wide: 1,547 out of 103,808
    • In microbiology: 167 out of 9,238
  • Year to date:
    • Site-wide: 424 out of 103,808
  • Since beginning of last month:
    • Site-wide: 5,425 out of 103,808

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide


Sign up for the Rxivist weekly newsletter! (Click here for more details.)